In­cyte's top­i­cal Jakafi scores again in eczema Phase III; Pri­or­i­ty re­view lines Roche's Tecen­triq up for new lung ...

6 years ago
News Briefing

DuPont makes an­oth­er for­ay in­to drug R&D, throw­ing its name in­to the mi­cro­bio­me hat

6 years ago
Deals

For two decades, a new vac­cine tech­nol­o­gy has been slow­ly ap­proach­ing prime time. Now, can it stop a pan­dem­ic?

6 years ago
R&D
In Focus

Cel­lec­tis boosts its cof­fers in re­vised off-the-shelf CAR-T deal with Servi­er

6 years ago
R&D

Bris­tol-My­ers shrugs off an­oth­er Op­di­vo com­bo flop as $1.74B deal goes pfffft

6 years ago
R&D

Biotech CEO who lied about cur­ing his own paral­y­sis sen­tenced to 7 years in jail

6 years ago
People

As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

6 years ago
Pharma
FDA+

Astel­las fol­lows up $3B gene ther­a­py buy­out with $109M plan to ac­cel­er­ate a man­u­fac­tur­ing boom

6 years ago
R&D

Af­ter dig­ging through dis­cards, biotech start­up is mak­ing a $45M bet it can fix a failed can­cer ther­a­py

6 years ago
Financing

Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

6 years ago
News Briefing

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on ...

6 years ago
R&D
In Focus

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

6 years ago
Financing

RA joins glob­al syn­di­cate to back a $98M round for CAN­bridge

6 years ago
Financing
China

Drug dis­cov­ery in HD: Ox­ford spin­of­f's mass spec­trom­e­try ap­proach scores fresh fund­ing

6 years ago
Financing
Startups

Chi­na ap­proves flu drug be­ing tout­ed as a po­ten­tial coro­n­avirus treat­ment amid a rush of clin­i­cal stud­ies

6 years ago
China
Coronavirus

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

6 years ago
R&D
FDA+

War­ren Buf­fett gets a dou­ble take as the in­vest­ment pow­er­house set­tles on its first biotech in­vest­ment

6 years ago
R&D

The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

6 years ago
Financing

For­mer No­var­tis ex­ec pleads guilty to gener­ic price fix­ing

6 years ago
Pharma

Palleon's first CSO ex­plains how they (and she) got here; En­ter­prise taps Roche and No­var­tis vet David Mor­ris as CMO

6 years ago
Peer Review

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to ...

6 years ago
Pharma

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

6 years ago
News Briefing

If you were a can­cer pa­tient, where would you rather be — the Unit­ed States or Eu­rope?

6 years ago
R&D

As­traZeneca's Chi­nese in­vest­ment bank part­ner rais­es $229M for its own new fund — and it's all about the ...

6 years ago
R&D
Coronavirus
First page Previous page 852853854855856857858 Next page Last page
A service from the Financial Times